Saturday 17 October 2026
Export FDMT’s income statement to Excel — free account
4D Molecular Therapeutics, Inc.
FDMT Healthcare Biotechnology
4D Molecular Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $85.2 million, up 230,194.6% from fiscal 2024. In the quarter to June 2026, revenue grew 25,106.7%, EPS fell 6.12% and free cash flow fell 61.3%, each against the same quarter a year earlier.
12.14
0.73
−5.67%
Follow FDMT
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
10.16 | 7.18 | 5.10 | 4,064.46 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(13.35) | (9.30) | 15.22 | (10.49) | |
P/B ratio |
2.29 | 1.40 | 0.86 | 1.32 | |
Price to Tangible BV |
2.29 | 1.40 | 0.86 | 1.32 | |
EV/Sales |
6.44 | 2.89 | 0.51 | 1,622.52 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(3.80) | (1.97) | (0.40) | (1.06) | |
EV/FCF |
(3.80) | (1.97) | (0.40) | (1.05) | |
Quick Ratio |
7.68 | 9.01 | 9.15 | 8.22 | |
Current Ratio |
8.03 | 9.34 | 9.39 | 8.42 | |
Net Debt/EBITDA |
4.45 | 5.32 | (27.24) | 4.99 | |
Debt/Assets |
3.98% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.05 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.19 | 0.17 | 0.15 | 0.00 | |
Operating CF/Net income |
0.96 | 0.99 | 1.47 | 0.82 | |
Capex/Depreciation |
(0.23) | 0.08 | 1.01 | 0.85 | |
Research and Development Expense of Revenue |
1,805.92% | 2,132.59% | 67.70% | 54,931.11% | |
Selling, General and Administrative Expense of Revenue |
331.24% | 383.56% | 15.00% | 13,152.22% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
155.62% | 146.14% | 6.53% | 5,021.11% | |
Graham Net Nets |
0.32 | 0.54 | 0.81 | 0.53 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(19.77%) | (27.60%) | (32.27%) | (43.15%) | |
Free Cash Flow Yield |
(16.69%) | (20.41%) | (25.23%) | (37.94%) | |
Revenue per Share |
0.05 | 0.04 | 1.47 | 0.00 | |
Operating CF per Share |
(1.00) | (1.00) | 0.49 | (0.83) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(1.00) | (1.00) | 0.49 | (0.83) | |
Cash per Share |
5.14 | 5.74 | 6.95 | 5.44 | |
Shareholders Equity per Share |
5.80 | 6.64 | 8.73 | 6.57 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
5.80 | 6.64 | 8.73 | 6.57 | |
Free Cash Flow |
(70.06) | (68.11) | 28.62 | (46.41) | |
Working Capital |
335.28 | 361.96 | 369.15 | 275.27 | |
Capital Expenditures |
(0.07) | 0.01 | 0.07 | 0.09 | |
Net Current Asset Value |
298.00 | 344.30 | 352.09 | 257.38 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.02 | 0.00 | 0.00 | (1.01) | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
2.91 | — | — | — | |
Average Payables |
10.61 | 9.42 | 7.77 | 4.89 | |
Average Assets |
483.13 | 514.32 | 563.55 | 514.01 | |
Average Common Equity |
414.27 | 460.78 | 508.13 | 460.97 |
Columns are period end dates